Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,129 GBX | -0.50% | +1.05% | +14.66% |
11:35am | AstraZeneca: CHMP recommends approval of Tagrisso in the EU | CF |
11:19am | AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.66% | 240B | |
+40.73% | 739B | |
+31.40% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+9.25% | 210B | |
-5.07% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Targets $80 Billion Revenue by 2030, Expects to Launch 20 New Medicines